- Home
- SRCE vs ELVN Comparison
SRCE vs ELVN Comparison
Compare SRCE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRCE | ELVN |
|---|---|---|
| Founded | 1863 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRCE | ELVN |
|---|---|---|
| Price | $68.64 | $31.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $73.25 | $41.00 |
| AVG Volume (30 Days) | 112.6K | ★ 758.9K |
| Earning Date | 04-23-2026 | 03-03-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ 19.59 | 3.17 |
| EPS | ★ 6.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.29 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $10.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.14 | $13.30 |
| 52 Week High | $71.98 | $31.76 |
Technical Indicators
Market Signals| Indicator | SRCE | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 62.25 |
| Support Level | $68.15 | $19.10 |
| Resistance Level | $69.29 | N/A |
| Average True Range (ATR) | 1.57 | 1.89 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 89.30 | 89.81 |
Price Performance
Historical ComparisonAbout SRCE 1st Source Corporation
1st Source Corp, along with its subsidiary, offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans, which are given to privately owned business clients mainly located within the regional market areas, Consumer Services that consist of the full range of consumer banking products and services, Trust and Wealth Advisory Services, and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.